Cognitive Therapy with Children and Families: Treating Internalizing Disorders

No description supplie

Additional file 1: Figure S1. of Does video feedback analysis improve CPR performance in phase 5 medical students?

Checklist assessment tool for scoring student performance. (PDF 188 kb

A facile preparation method for nanosized MOFs as a multifunctional material for cellular imaging and drug delivery

<p>Tb-based metal-organic framework nanoparticles (Tb-MOF NPs) with good colloidal stability and stable fluorescence properties in an aqueous solution were prepared by a simple mechanical grinding of Tb-MOF with a biocompatible polymer surfactant (F127). The characteristic fluorescence property of Tb-MOF NPs allowed us to use this nanomaterial as a cell imaging probe. Efficient cellular uptake of Tb-MOF NPs apparently via an energy-dependent endocytosis was observed by confocal laser scanning microscopy. By taking advantage of the porous nature of the Tb-MOF NPs an anticancer drug (doxorubicin) was successfully loaded and delivered to kill cancer cells to demonstrate their usage as a drug delivery vehicle. This simple grinding method afforded a nanosized, multifunctional biomaterial that was used for cell imaging and drug delivery, and it can be extended to other MOFs to widen their applications.</p

Evaluation of a patient self-directed mealtime insulin titration algorithm: a US payer perspective

<p><b>Objective</b> To model the potential economic impact of implementing the AUTONOMY once daily (Q1D) patient self-titration mealtime insulin dosing algorithm vs standard of care (SOC) among a population of patients with Type 2 diabetes living in the US.</p> <p><b>Methods</b> Three validated models were used in this analysis: The Treatment Transitions Model (TTM) was used to generate the primary results, while both the Archimedes (AM) and IMS Core Diabetes Models (IMS) were used to test the veracity of the primary results produced by TTM. Models used data from a ‘real world’ representative sample of patients (2012 US National Health and Nutrition Examination Survey) that matched the characteristics of US patients enrolled in the randomized controlled trial ‘AUTONOMY’ cohort. The base-case time horizon was 10 years.</p> <p><b>Results</b> The modeling results from TTM demonstrated that total costs in the base-case were reduced by $1732, with savings predicted to occur as early as year 1. Results from the three models were consistent, showing a reduction in total costs for all sensitivity analyses.</p> <p><b>Limitations</b> Data from short-term clinical trials were used to develop long-term projections. The nature of such extrapolation leads to increased uncertainty.</p> <p><b>Conclusion</b> The results from all three models indicate that the AUTONOMY Q1D algorithm has the potential to abate total costs as early as the first year.</p

The preclinical venom-neutralising efficacy (antivenom ED₅₀) of the PANAF (PS&V) and Panafrican (ICP) antivenoms compared to SAIMR Polyvalent in the pre-incubation model of envenoming.

ED50 is defined as the volume of antivenom which protects 50% of mice from the lethal effects of venom. Each experiment used five mice per dose group. The assays utilised a venom challenge dose of 5 x venom LD50s (Table 2), except when it was necessary to reduce the challenge dose 3 x venom LD50s (indicated by red text). In these instances, the maximum volume limit of antivenom that can be injected intravenously was reached without reducing the venom lethality of the 5 x LD50 venom dose, therefore it was necessary to reduce the venom dose to determine an ED50 for the antivenom. Results are reported as ED50 determined by Probit analyses and expressed in (i) volume of antivenom and (ii) as μL of antivenom per mg of venom. 95% confidence intervals are reported in parentheses.</p

PLA₂ assay optimisation data.

(XLSX)</p

SVMP assay raw data.

(XLSX)</p

The titre of three antivenoms against five Eswatini venoms determined by end-point titration ELISA.

SAIMR Polyvalent (SAVP) shown in teal, Panafrican (ICP) shown in magenta, PANAF (PS&V) shown in blue, normal horse IgG shown in purple. Panel A: B. arietans. Panel B: D. polylepis. Panel C: H. haemachatus. Panel D: N. annulifera. Panel E: N. mossambica. Data points represent the mean of two replicates and error bars show the standard deviation. The vertical line at the 1:62,500 dilution represents the point at which Ig titres of each antivenom were compared.</p

ELISA endpoint raw data and ELISA avidity raw data.

(XLSX)</p

Protein profiles of the venom protein components of five Eswatini snakes.

A: Venom proteins separated by SDS-PAGE under reducing conditions and stained with Coomassie blue to show all proteinaceous components. B: Immunoblot using normal horse IgG used as primary antibody negative control. C: Immunoblot using SAIMR Polyvalent as primary antibody. D: Immunoblot using Panafrican (ICP) antivenom as primary antibody. E: Immunoblot using PANAF (PS&V) antivenom as primary antibody.</p